2 citations
,
November 1990 in “International Journal of Dermatology” Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.
May 2021 in “Journal of the Endocrine Society” A woman's severe hormone imbalance after menopause led to finding a rare ovarian tumor, treated by surgery.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
1 citations
,
November 2025 in “Neuro-Oncology” Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
26 citations
,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
101 citations
,
January 1985 in “British Journal of Dermatology” Spironolactone is effective for treating acne, hirsutism, and androgenic alopecia in women with few side effects.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
July 2024 in “Journal of the ASEAN Federation of Endocrine Societies” In post-menopausal women, signs of increased male hormones should be checked for possible ovarian cancer.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
23 citations
,
February 2010 in “European Journal of Medicinal Chemistry”
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
July 2023 in “Journal of exploratory research in pharmacology” A new psoriasis lotion called "Psorisbye" improved symptoms in a patient within one week.
April 2026 in “Phytotherapy Research” Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
August 2019 in “Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)” PCOS treatment combines lifestyle changes and medication to manage symptoms and reduce health risks.
33 citations
,
April 2015 in “Cochrane library” Some medicines can reduce excessive hair growth in women, but more research is needed to compare treatments and consider side effects.
14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
1 citations
,
March 2017 in “European Journal of Cancer Prevention” COCs often cause nausea, vomiting, and hair loss, while Depo-Provera is linked to weight gain.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
4 citations
,
March 2021 in “Case Reports” A woman's excessive hair growth and masculine features were due to a rare benign ovarian tumor and endometrial cancer, which improved after surgery.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.